Companies › Innovent Biopharmaceutical Technology (Hangzhou)
7 active drug programs in 178 registered trials: 140 Phase 2, 20 Phase 3, 18 Phase 1; Oncology, Immunology, Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Picankibart | – | Phase 3 | Plaque Psoriasis; Psoriatic Arthritis | Jan 2027 |
| IBI354 Anti-HER2 antibody | ERBB2 | Phase 3 | HER2-positive Breast Cancer | Apr 2028 |
| IBI112 IL-23 inhibitor | IL23A | Phase 3 | Psoriasis | Jan 2029 |
| IBI310 CTLA-4 inhibitor | CTLA4 | Phase 2 | Hepatocellular Carcinoma (HCC); Neuroendocrine Neoplasm; Gastric Cancer | Dec 2027 |
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Hepatocellular Carcinoma (HCC); Resectable Gastric/Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Squamous Cell Non-small Cell Lung Cancer … | Dec 2027 |
| Ipilimumab (N01) Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 2 | Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Dec 2031 |
| IBI3028 Recombinant anti-EGFR and c-Met antibodies dual-payload conjugate | EGFR, MET | Phase 1 | Solid Tumor | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03869034 | Sintilimab | Phase 2 | Hepatocellular Carcinoma | Oncology | Jul 2020 |
| NCT03869034 | Sintilimab | Phase 2 | Hepatocellular Carcinoma | Oncology | Jul 2020 |
| NCT04940546 | Sintilimab | Phase 1 | Colorectal Cancer Metastatic | Oncology | Oct 2023 |
| NCT05177068 | Sintilimab | Phase 2 | Gastric Cancer | Oncology | Oct 2024 |
| NCT06808412 | Sintilimab | Phase 2 | Rcctal Cancer | Oncology | May 2025 |
| NCT06787911 | Sintilimab | Phase 2 | Thyroid Cancer | Oncology | May 2025 |
| NCT04295317 | Sintilimab | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Jun 2025 |
| NCT06776757 | Sintilimab | Phase 1 | Metastatic Colorectal Cancer | Oncology | Jun 2025 |
| NCT06054906 | Sintilimab | Phase 2 | Gastric Cancer | Oncology | Jun 2025 |
| NCT05010681 | Sintilimab | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Aug 2025 |
| NCT06718205 | Sintilimab | Phase 2 | Esophageal Cancer | Oncology | Sep 2025 |
| NCT05165407 | Sintilimab | Phase 2 | Neuroendocrine Neoplasm | Oncology | Sep 2025 |
| NCT05165407 | IBI310 | Phase 2 | Neuroendocrine Neoplasm | Oncology | Sep 2025 |
| NCT05098847 | Sintilimab | Phase 2 | Liver Metastasis | Oncology | Oct 2025 |
| NCT06583083 | Sintilimab | Phase 2 | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Oncology | Aug 2026 |
| NCT06759064 | Sintilimab | Phase 1 | Cancer of Stomach, Adenocarcinoma | Oncology | Sep 2026 |
| NCT05057052 | Sintilimab | Phase 2 | Liver Metastases | Oncology | Sep 2026 |
| NCT06356584 | Sintilimab | Phase 2 | Colorectal Cancer | Oncology | Oct 2026 |
| NCT07750951 | Sintilimab | Phase 2 | MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma | Oncology | Nov 2026 |
| NCT06563869 | Sintilimab | Phase 3 | Esophageal Squamous Cell Carcinoma | Oncology | Nov 2026 |
| NCT06091423 | Sintilimab | Phase 2 | Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Oncology | Nov 2026 |
| NCT05429463 | Sintilimab | Phase 3 | Squamous Cell Non-small Cell Lung Cancer | Oncology | Nov 2026 |
| NCT06767007 | Sintilimab | Phase 2 | Unresectable Locally Recurrent Rectal Cancer | Oncology | Nov 2026 |
| NCT04512534 | Sintilimab | Phase 2 | Peripheral T-cell Lymphoma | Oncology | Dec 2026 |
| NCT04512534 | Sintilimab | Phase 2 | Peripheral T-cell Lymphoma | Oncology | Dec 2026 |
| NCT06714708 | Sintilimab | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT05593458 | Sintilimab | Phase 3 | Locally Advanced Gastric Carcinoma | Oncology | Dec 2026 |
| NCT05918094 | Sintilimab | Phase 3 | Gastric Cancer | Oncology | Dec 2026 |
| NCT06685276 | Sintilimab | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT04331093 | Sintilimab | Phase 2 | Acral Melanoma | Oncology | Dec 2026 |
| NCT05512351 | Sintilimab | Phase 2 | Oligodendroglioma | Oncology | Dec 2026 |
| NCT06050317 | Sintilimab | Phase 2 | Pancreas Cancer | Oncology | Dec 2026 |
| NCT05507632 | Sintilimab | Phase 2 | Unresectable Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT05757336 | Sintilimab | Phase 2 | Gallbladder Cancer | Oncology | Dec 2026 |
| NCT05171660 | Sintilimab | Phase 3 | Colorectal Cancer Stage IV | Oncology | Dec 2026 |
| NCT06314334 | Sintilimab | Phase 2 | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Oncology | Dec 2026 |
| NCT05220267 | Sintilimab | Phase 2 | Non Clear Cell Renal Carcinoma | Oncology | Dec 2026 |
| NCT06031285 | Sintilimab | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT05400070 | Sintilimab | Phase 2 | Sintilimab | Oncology | Dec 2026 |
| NCT06391190 | Sintilimab | Phase 1 | Locally Advanced Cervical Carcinoma | Oncology | Dec 2026 |
| NCT06775743 | Sintilimab | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Dec 2026 |
| NCT06812039 | Sintilimab | Phase 2 | Hepato Cellular Carcinoma (HCC) | Oncology | Dec 2026 |
| NCT07257653 | Sintilimab | Phase 2 | Colorectal Neoplasms | Oncology | Dec 2026 |
| NCT04833387 | Sintilimab | Phase 2 | Colorectal Carcinoma | Oncology | Dec 2026 |
| NCT05481476 | Sintilimab | Phase 2 | Pancreatic Neoplasms | Oncology | Dec 2026 |
| NCT07501351 | Sintilimab | Phase 2 | Hepatocellulcar Carcinoma | Oncology | Dec 2026 |
| NCT04836728 | Sintilimab | Phase 2 | Non-small Cell Lung Cancer Metastatic | Oncology | Dec 2026 |
| NCT07394387 | Sintilimab | Phase 2 | Triple Negative Breast Cancer (TNBC) | Oncology | Dec 2026 |
| NCT06341595 | Sintilimab | Phase 2 | Gastric Cancer | Oncology | Dec 2026 |
| NCT06555471 | Sintilimab | Phase 2 | Gastric Cancer | Oncology | Dec 2026 |
| NCT03950271 | Sintilimab | Phase 2 | Gastric Cancer | Oncology | Dec 2026 |
| NCT04961515 | Sintilimab | Phase 2 | Primary Central Nervous System Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT07852091 | Sintilimab | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT06730373 | Sintilimab | Phase 2 | HER2-positive Gastric Cancer | Oncology | Dec 2026 |
| NCT07468630 | Sintilimab | Phase 2 | Colon Adenocarcinoma | Oncology | Dec 2026 |
| NCT07468630 | Sintilimab | Phase 2 | Colon Adenocarcinoma | Oncology | Dec 2026 |
| NCT06013618 | Sintilimab | Phase 2 | Neuroblastoma | Oncology | Dec 2026 |
| NCT06494943 | Sintilimab | Phase 1 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT05979818 | Sintilimab | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06742411 | Sintilimab | Phase 1 | Gastric (Stomach) Cancer | Oncology | Dec 2026 |
The 60 nearest readouts of 178 trials; the rest in the app.
AstraZeneca Shanghai Henlius Biotech Beijing Biotech Johnson & Johnson (Janssen) Sichuan Baili Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Akeso Shenyang Sunshine Pharmaceutical Innovent Biologics (Suzhou)
Lepu Biopharma R-Pharm Chipscreen Biosciences BeiGene mAbxience Research
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.